Coronavirus disease

Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™

Retrieved on: 
Monday, March 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Monoclonal antibodies, Oportuzumab monatox, Coronavirus disease, Health, Medical specialties, Vicineum™, Non-Muscle Invasive Bladder Cancer, Sesen Bio

We will continue working collaboratively with the EMA to move Vicineum through the regulatory process as expeditiously as possible.

Key Points: 
  • We will continue working collaboratively with the EMA to move Vicineum through the regulatory process as expeditiously as possible.
  • Sesen Bio is currently going through the tradename approval process with the EMA for oportuzumab monatox.
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
  • Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

Retrieved on: 
Monday, March 8, 2021
Medicine, Medical specialties, Clinical medicine, Glycoproteins, Immunology, Medical tests, Immunologic tests, Medical terminology, Rapid antigen test, Coronavirus disease, Immunoglobulin G, Antibody

With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.

Key Points: 
  • With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.
  • These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples.
  • These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • Ortho plans to manufacture several million COVID-19 antibody tests each month in Pencoed, Wales.

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Glycoproteins, Medical terminology, Rapid antigen test, Coronavirus disease, Antibody, Variants of SARS-CoV-2, COVID-19 testing, ELISA

- These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .

Key Points: 
  • - These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • With both assays showing 100% specificityiand excellent sensitivity,iiOrtho's new COVID-19 Total 2 and IgG 2 antibody assays help clinicians understand each patient's adaptive immune response (acquired naturally post-infection or through vaccination) to SARS-CoV-2.
  • These new anti-SARS-CoV-2 antibody assays are the latest addition to Ortho's COVID-19 solutions, which include COVID-19 antibody tests and an antigen test .
  • Ortho plans to manufacture several million COVID-19 antibody tests each month in Pencoed, Wales.

CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19

Retrieved on: 
Monday, March 8, 2021
Clinical trials, Health, Leronlimab, Medical statistics, Clinical endpoint, Coronavirus disease, Articles

MHRA has told the Company it will accept more data from the open-label portion of the current CD12 trial.

Key Points: 
  • MHRA has told the Company it will accept more data from the open-label portion of the current CD12 trial.
  • The Company anticipates the Health Canada Interim Order (IO) could allow the Company to sell leronlimab in Canada, while additional critical COVID-19 patients are enrolled.
  • These discussions are on going, and the Company has initiated the process to submit an IO with Health Canada.
  • 3) Amongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant.

COVID-19 Detection Kits Market Size To Reach $4.63 Billion By 2027, To Be Driven By Constant Growth in Delivery of Molecular Test Kits | Million Insights

Retrieved on: 
Monday, March 8, 2021
Life sciences, Articles, Natural sciences, Biotechnology, Molecular biology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Coronavirus disease

What are the Driving Factors for the COVID-19 Detection Kits Market?

Key Points: 
  • What are the Driving Factors for the COVID-19 Detection Kits Market?
  • Consequently, the kits for RT-PCR centered molecular analyze are observing a massive augmentation in demand, through the world.
  • The constant growth in the delivery of the molecular test kits describes the towering demand for the COVID-19 detection kits
    Please click here to get the sample pdf and find more details on "COVID-19 Detection Kits Market"Report 2027.
  • Browse 150 page research report with TOC on "Global COVID-19 Detection Kits Market" at: https://www.millioninsights.com/industry-reports/global-covid-19-detecti...
    Million Insights segmented the global COVID-19 detection kits market based on End Use, Mode, Sample Type, Product, and Region:
    COVID-19 Detection Kits Products Outlook (Revenue, USD Million, 2020 - 2027)
    COVID-19 Detection Kits Sample Type Outlook (Revenue, USD Million, 2020 - 2027)

COVID-19 Detection Kits Market Size To Reach $4.63 Billion By 2027, To Be Driven By Constant Growth in Delivery of Molecular Test Kits | Million Insights

Retrieved on: 
Monday, March 8, 2021
Life sciences, Articles, Natural sciences, Biotechnology, Molecular biology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Coronavirus disease

What are the Driving Factors for the COVID-19 Detection Kits Market?

Key Points: 
  • What are the Driving Factors for the COVID-19 Detection Kits Market?
  • Consequently, the kits for RT-PCR centered molecular analyze are observing a massive augmentation in demand, through the world.
  • The constant growth in the delivery of the molecular test kits describes the towering demand for the COVID-19 detection kits
    Please click here to get the sample pdf and find more details on "COVID-19 Detection Kits Market"Report 2027.
  • Browse 150 page research report with TOC on "Global COVID-19 Detection Kits Market" at: https://www.millioninsights.com/industry-reports/global-covid-19-detecti...
    Million Insights segmented the global COVID-19 detection kits market based on End Use, Mode, Sample Type, Product, and Region:
    COVID-19 Detection Kits Products Outlook (Revenue, USD Million, 2020 - 2027)
    COVID-19 Detection Kits Sample Type Outlook (Revenue, USD Million, 2020 - 2027)

Genetic Testing Market Report 2021- Global Growth, Trends, Covid-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021
Health, Genetics, Medicine, Health, Clinical medicine, Occupational safety and health, Atypical pneumonias, Sarbecovirus, Medical tests, Pandemics, Genetic testing, Coronavirus disease, COVID-19 pandemic, Severe acute respiratory syndrome coronavirus

The "Genetic Testing Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genetic Testing Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has left a significant impact on the growth of the genetic testing market over the crisis.
  • Most of the genetic testing services have adopted virtualization, along with home testing kit/home sample collection to combat the transmission of the SARS-CoV2 virus.
  • The product advancements and improvements in genetic testing platforms by the major players are increasing competitive rivalry.

CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19

Retrieved on: 
Sunday, March 7, 2021
Clinical trials, Health, Leronlimab, Medical statistics, Clinical endpoint, Coronavirus disease, Articles

MHRA has told the Company it will accept more data from the open-label portion of the current CD12 trial.

Key Points: 
  • MHRA has told the Company it will accept more data from the open-label portion of the current CD12 trial.
  • The Company anticipates the Health Canada Interim Order (IO) could allow the Company to sell leronlimab in Canada, while additional critical COVID-19 patients are enrolled.
  • These discussions are on going, and the Company has initiated the process to submit an IO with Health Canada.
  • 3) Amongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant.

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Retrieved on: 
Saturday, March 6, 2021
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Infectious diseases, Clinical trials, Sarbecovirus, Respiratory diseases, Medical specialties, Health, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, Molnupiravir, Severe acute respiratory syndrome, Conference on Retroviruses and Opportunistic Infections, Molnupiravir, Ridgeback Biotherapeutics, Merck

These preliminary findings were presented today during Science SpotlightsTM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021).

Key Points: 
  • These preliminary findings were presented today during Science SpotlightsTM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021).
  • Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting.
  • Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection.
  • In addition to the ongoing clinical studies, Merck has conducted a comprehensive nonclinical program to characterize the safety profile of molnupiravir.

Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

Retrieved on: 
Friday, March 5, 2021
Medicine, Health sciences, Health, COVID-19 testing, Coronavirus disease, Emergency Use Authorization, Severe acute respiratory syndrome coronavirus, COVID-19 vaccine, DiaSorin

SILVER SPRING, Md., March 5, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies.

Key Points: 
  • SILVER SPRING, Md., March 5, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies.
  • The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.
  • "The T-Detect COVID Test is a novel technology that assesses the T cell immune response to COVID-19.
  • The T-Detect COVID test will be a useful tool to help determine if a person previously had COVID-19.